Tissue factor signalling modifies the expression and regulation of G1/S checkpoint regulators: Implications during injury and prolonged inflammation

Featherby,Sophie J.; Faulkner,Eamon C.; Ettelaie,Camille

doi:10.3892/mmr.2024.13404

Tissue factor signalling modifies the expression and regulation of G1/S checkpoint regulators: Implications during injury and prolonged inflammation

Authors:
- Sophie J. Featherby
- Eamon C. Faulkner
- Camille Ettelaie
View Affiliations

Affiliations: Biomedical Section, Hull-York Medical School, University of Hull, Hull, HU6 7RX, UK
Published online on: November 26, 2024 https://doi.org/10.3892/mmr.2024.13404
Article Number: 39
Copyright: © Featherby et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tissue factor (TF) possesses additional physiological functions beyond initiating the coagulation cascade. Cellular signals initiated by cellular TF or on contact with TF‑containing microvesicles, contribute to wound healing through regulating a number of cellular properties and functions. TF regulates the cell cycle checkpoints, however the underlying signalling mechanisms have not been determined. Endothelial (human dermal blood endothelial cells and human umbilical vein endothelial cells) and epithelial [human telomerase reverse transcriptase‑human pancreatic nestin‑expressing ductal cells (hTERT‑HPNE) and AsPC‑1] cells were exposed to different concentrations of recombinant TF, and the influence on G1/S checkpoint regulators examined. Short‑term exposure to a lower concentration of TF promoted increased p16^INKa and decreased p21^CIP1/WAF1 expression, together with higher early region 2 binding factor (E2F) transcriptional activity and increased phosphorylation of Thr821/826 within retinoblastoma protein, leading to cell proliferation. The increase in p16^INKa expression was prevented following inhibition of β1‑integrin, or blocking the exosite within TF with AIIB2 and 10H10 antibodies, respectively. Exposure of cells to higher concentrations of TF induced disproportionate increases in p16^INKa and p21^CIP1/WAF1 expression, reduced retinoblastoma protein phosphorylation and E2F activity. Prolonged treatment of the immortalised hTERT‑HPNE cells with recombinant TF, resulted in significant downregulation of p16^INKa protein, which was partially due to reduced mRNA expression, together with increased E2F activity, and cyclin E mRNA expression. Although an increase in the methylation of the p16^INKa promoter was detected, the reduction in p16^INKa protein was concurrent with, and partly attributed to increased p14^ARF expression. TF appears early at the site of trauma, and its concentration is an ideal gauge for determining the extent of cellular damage, initiating clearance and repair. It is hypothesised that the balance of this signal is also dependent on the ability of cells to moderate the TF, and therefore on the level of damage. However, prolonged exposure of cells for example due to inflammation, leads to the dysregulation of the G1/S checkpoint by the tumour suppressors, leading to aberrant growth.

View Figures

View References

1	De Blaineville HMD: Injection de matière cerebrale dans des veines. Gaz Med Paris (Ser. 2). 1834.2524
2	Bächli E: History of tissue factor. Br J Haematol. 110:248–255. 2000.PubMed/NCBI
3	Howell WH: The nature and action of the thromboplastin (zymoplastic) substance of the tissues. Am J Physiol. 1:31–59. 1912.
4	Zelaya H, Rothmeier AS and Ruf W: Tissue factor at the crossroad of coagulation and cell signaling. J Thromb Haemost. 16:1941–1952. 2018. View Article : Google Scholar : PubMed/NCBI
5	Carson SD and Konigsberg WH: Lipid activation of coagulation factor III apoprotein (tissue factor)-Reconstitution of the protein-membrane complex. Thromb Haemost. 44:12–15. 1980. View Article : Google Scholar : PubMed/NCBI
6	Kurosawa S, Matsuda M and Aoki N: Urinary procoagulant behaves as tissue factor by promoting factor VIIa-catalyzed activation of factor X. Thromb Res. 33:595–606. 1984. View Article : Google Scholar : PubMed/NCBI
7	Sanders NL, Bajaj SP, Zivelin A and Rapaport SI: Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood. 66:204–212. 1985. View Article : Google Scholar : PubMed/NCBI
8	Hisada Y and Mackman N: Tissue factor and cancer: Regulation, tumor growth, and metastasis. Semin Thromb Hemost. 45:385–395. 2019. View Article : Google Scholar : PubMed/NCBI
9	McVey JH: The role of the tissue factor pathway in haemostasis and beyond. Curr Opin Hematol. 23:453–461. 2016. View Article : Google Scholar : PubMed/NCBI
10	Rondon AMR, Kroone C, Kapteijn MY, Versteeg HH and Buijs JT: Role of tissue factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 45:396–412. 2019. View Article : Google Scholar : PubMed/NCBI
11	Cimmino G and Cirillo P: Tissue factor: Newer concepts in thrombosis and its role beyond thrombosis and hemostasis. Cardiovasc Diagn Ther. 8:581–593. 2018. View Article : Google Scholar : PubMed/NCBI
12	Li H, Yu Y, Gao L, Zheng P, Liu X and Chen H: Tissue factor: A neglected role in cancer biology. J Thromb Thrombolysis. 54:97–108. 2022. View Article : Google Scholar : PubMed/NCBI
13	Rao LV and Pendurthi UR: Tissue factor-factor VIIa signaling. Arter. Thromb Vasc Biol. 25:47–56. 2005. View Article : Google Scholar : PubMed/NCBI
14	Rak J, Milsom C and Yu J: Tissue factor in cancer. Curr Opin Hematol. 15:522–528. 2008. View Article : Google Scholar : PubMed/NCBI
15	Schaffner F and Ruf W: Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol. 29:1999–2004. 2009. View Article : Google Scholar : PubMed/NCBI
16	Nemerson Y and Repke D: Tissue factor accelerates the activation of coagulation factor VII: The role of a bifunctional coagulation cofactor. Thromb Res. 40:351–358. 1985. View Article : Google Scholar : PubMed/NCBI
17	Rao LV, Rapaport SI and Bajaj SP: Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood. 68:685–691. 1986. View Article : Google Scholar : PubMed/NCBI
18	Madkhali Y, Featherby S, Collier ME, Maraveyas A, Greenman J and Ettelaie C: The Ratio of Factor VIIa:Tissue Factor content within microvesicles determines the differential influence on endothelial cells. TH Open. 3:e132–e145. 2019. View Article : Google Scholar : PubMed/NCBI
19	Pradier A and Ettelaie C: The influence of exogenous tissue factor on the regulators of proliferation and apoptosis in endothelial cells. J Vasc Res. 45:19–32. 2008. View Article : Google Scholar : PubMed/NCBI
20	ElKeeb AM, Collier ME, Maraveyas A and Ettelaie C: Accumulation of tissue factor in endothelial cells induces cell apoptosis, mediated through p38 and p53 activation. Thromb Haemost. 114:364–378. 2015. View Article : Google Scholar : PubMed/NCBI
21	Ethaeb AM, Mohammad MA, Madkhali Y, Featherby S, Maraveyas A, Greenman J and Ettelaie C: Accumulation of tissue factor in endothelial cells promotes cellular apoptosis through over-activation of Src1 and involves β1-integrin signalling. Apoptosis. 25:29–41. 2020. View Article : Google Scholar : PubMed/NCBI
22	Madkhali Y, Rondon AMR, Featherby S, Maraveyas A, Greenman J and Ettelaie C: Factor VIIa regulates the level of cell-surface tissue factor through separate but cooperative mechanisms. Cancers (Basel). 13:37182021. View Article : Google Scholar : PubMed/NCBI
23	Huang SZ, Wei MN, Huang JR, Zhang ZJ, Zhang WJ, Jiang QW, Yang Y, Wang HY, Jin HL, Wang K, et al: Targeting TF-AKT/ERK-EGFR pathway suppresses the growth of hepatocellular carcinoma. Front Oncol. 9:1502019. View Article : Google Scholar : PubMed/NCBI
24	Kakkar AK, Lemoine NR, Scully MF, Tebbutt S and Williamson RC: Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg. 82:1101–1104. 1995. View Article : Google Scholar : PubMed/NCBI
25	Ettelaie C, Collier MEW, Featherby S, Benelhaj NE, Greenman J and Maraveyas A: Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: Correlation with tissue factor and PAR2 expression. Thromb J. 14:22016. View Article : Google Scholar : PubMed/NCBI
26	Nakayama K and Nakayama K: Cip/Kip cyclin-dependent kinase inhibitors: Brakes of the cell cycle engine during development. Bioessays. 20:1020–1029. 1998. View Article : Google Scholar : PubMed/NCBI
27	Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 287:821–828. 1999. View Article : Google Scholar : PubMed/NCBI
28	Harper JW: Cyclin dependent kinase inhibitors. Cancer Surv. 29:91–107. 1997.PubMed/NCBI
29	Vidal A and Koff A: Cell-cycle inhibitors: Three families united by a common cause. Gene. 247:1–15. 2000. View Article : Google Scholar : PubMed/NCBI
30	Cánepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF and Ogara MF: INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life. 59:419–426. 2007. View Article : Google Scholar : PubMed/NCBI
31	Blagosklonny MV and Pardee AB: The restriction point of the cell cycle. Cell Cycle. 1:103–110. 2002. View Article : Google Scholar : PubMed/NCBI
32	Abbas T and Dutta A: p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
33	Kreis NN, Louwen F and Yuan J: The multifaceted p21 (Cip1/Waf1/CDKN1A) in cell differentiation, migration and cancer therapy. Cancers (Basel). 11:12202019. View Article : Google Scholar : PubMed/NCBI
34	Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM and Sherr CJ: The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571–1583. 1999. View Article : Google Scholar : PubMed/NCBI
35	Gartel AL: Is p21 an oncogene? Mol Cancer Ther. 5:1385–1386. 2006. View Article : Google Scholar : PubMed/NCBI
36	Qureshi AW, Altamimy R, El Habhab A, El Itawi H, Farooq MA, Zobairi F, Hasan H, Amoura L, Kassem M, Auger C, et al: Ageing enhances the shedding of splenocyte microvesicles with endothelial pro-senescent effect that is prevented by a short-term intake of omega-3 PUFA EPA:DHA 6:1. Biochem Pharmacol. 173:1137342020. View Article : Google Scholar : PubMed/NCBI
37	Abbas M, Jesel L, Auger C, Amoura L, Messas N, Manin G, Rumig C, León-González AJ, Ribeiro TP, Silva GC, et al: Endothelial microparticles from acute coronary syndrome patients induce premature coronary artery endothelial cell aging and thrombogenicity: Role of the Ang II/AT1 Receptor/NADPH Oxidase-mediated activation of MAPKs and PI3-Kinase pathways. Circulation. 135:280–296. 2017. View Article : Google Scholar : PubMed/NCBI
38	Hempel D, Sierko E and Wojtukiewicz MZ: Protease-activated receptors-biology and role in cancer. Postepy Hig Med Dosw (Online). 70:775–786. 2016. View Article : Google Scholar : PubMed/NCBI
39	Ruf W: Roles of factor Xa beyond coagulation. J Thromb Thrombolysis. 52:391–396. 2021. View Article : Google Scholar : PubMed/NCBI
40	Koizume S and Miyagi Y: Tissue factor in cancer-associated thromboembolism: Possible mechanisms and clinical applications. Br J Cancer. 127:2099–2107. 2022. View Article : Google Scholar : PubMed/NCBI
41	Wojtukiewicz MZ, Hempel D, Sierko E, Tucker SC and Honn KV: Protease-activated receptors (PARs)-biology and role in cancer invasion and metastasis. Cancer Metastasis Rev. 34:775–796. 2015. View Article : Google Scholar : PubMed/NCBI
42	Dorfleutner A, Hintermann E, Tarui T, Takada Y and Ruf W: Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell. 15:4416–4425. 2004. View Article : Google Scholar : PubMed/NCBI
43	Kocatürk B and Versteeg HH: Tissue factor-integrin interactions in cancer and thrombosis: Every Jack has his Jill. J Thromb Haemost. 11 (Suppl 1):S285–S293. 2013. View Article : Google Scholar
44	Collier ME and Ettelaie C: Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves beta1-integrin and extracellular signal regulated kinase activation. Arterioscler Thromb Vasc Biol. 30:1810–1817. 2010. View Article : Google Scholar : PubMed/NCBI
45	Mirza H, Yatsula V and Bahou WF: The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells-Molecular characterization and evidence for functional coupling to the thrombin receptor. J Clin Invest. 97:1705–1714. 1996. View Article : Google Scholar : PubMed/NCBI
46	Xie L, Duan Z, Liu C, Zheng Y and Zhou J: Protease-activated receptor 2 agonist increases cell proliferation and invasion of human pancreatic cancer cells. Exp Ther Med. 9:239–244. 2015. View Article : Google Scholar : PubMed/NCBI
47	Hu L, Xia L, Zhou H, Wu B, Mu Y, Wu Y and Yan J: TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCα and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620. Tumour Biol. 34:2573–2581. 2013. View Article : Google Scholar : PubMed/NCBI
48	R&D Biosystems Quantikine ELISA Human Coagulation Factor III/Tissue Factor protocol, . chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.bio-techne.com/datasheet-pdf?src=rnd&pdf=dcf300.pdf2016.
49	Khorana AA, Francis CW, Menzies KE, Wang JG, Hyrien O, Hathcock J, Mackman N and Taubman MB: Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 6:1983–1985. 2008. View Article : Google Scholar : PubMed/NCBI
50	Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM and Ruf W: Inhibition of tissue factor signaling suppresses tumor growth. Blood. 111:190–199. 2008. View Article : Google Scholar : PubMed/NCBI
51	Carson SD, Ross SE, Bach R and Guha A: An inhibitory monoclonal antibody against human tissue factor. Blood. 70:490–493. 1987. View Article : Google Scholar : PubMed/NCBI
52	Ettelaie C, Collier ME, Mei MP, Xiao YP and Maraveyas A: Enhanced binding of tissue factor-microparticles to collagen-IV and fibronectin leads to increased tissue factor activity in vitro. Thromb Haemost. 109:61–71. 2013. View Article : Google Scholar : PubMed/NCBI
53	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
54	Zheng N, Fraenkel E, Pabo CO and Pavletich NP: Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev. 13:666–674. 1999. View Article : Google Scholar : PubMed/NCBI
55	Adrian R, Black AR and Azizkhan-Clifford J: Regulation of E2F: A family of transcription factors involved in proliferation control. Genes. 237:281–302. 1999.
56	Aksoy O, Chicas A, Zeng T, Zhao Z, McCurrach M, Wang X and Lowe SW: The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev. 26:1546–1557. 2012. View Article : Google Scholar : PubMed/NCBI
57	Rabinovich A, Jin VX, Rabinovich R, Xu X and Farnham PJ: E2F in vivo binding specificity: Comparison of consensus versus nonconsensus binding sites. Genome Res. 18:1763–1777. 2008. View Article : Google Scholar : PubMed/NCBI
58	Ertosun MG, Hapil FZ and Osman Nidai O: E2F1 transcription factor and its impact on growth factor and cytokine signaling. Cytokine Growth Factor Rev. 31:17–25. 2016. View Article : Google Scholar : PubMed/NCBI
59	Collier MEW, Akinmolayan A and Goodall AH: Comparison of tissue factor expression and activity in foetal and adult endothelial cells. Blood Coagul Fibrinolysis. 28:452–459. 2017. View Article : Google Scholar : PubMed/NCBI
60	Noble JR, Zhong ZH, Neumann AA, Melki JR, Clark SJ and Reddel RR: Alterations in the p16(INK4a) and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts. Oncogene. 23:3116–3121. 2004. View Article : Google Scholar : PubMed/NCBI
61	Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS and Knowles MA: Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene. 25:5037–5045. 2006. View Article : Google Scholar : PubMed/NCBI
62	Collier ME and Ettelaie C: Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J Biol Chem. 286:11977–11984. 2011. View Article : Google Scholar : PubMed/NCBI
63	Georgiadou D, Sergentanis TN, Sakellariou S, Filippakis GM, Zagouri F, Vlachodimitropoulos D, Psaltopoulou T, Lazaris AC, Patsouris E and Zografos GC: Cyclin D1, p16(INK) (4A) and p27(Kip1) in pancreatic adenocarcinoma: Assessing prognostic implications through quantitative image analysis. APMIS. 122:1230–1239. 2014. View Article : Google Scholar : PubMed/NCBI
64	Tsiambas E, Karameris A, Gourgiotis S, Salemis N, Athanassiou AE, Karakitsos P, Papalois A, Merikas E, Kosmidis P and Patsouris E: Simultaneous deregulation of p16 and cyclin D1 genes in pancreatic ductal adenocarcinoma: A combined immunohistochemistry and image analysis study based on tissue microarrays. J BUON. 12:261–267. 2007.PubMed/NCBI
65	Kreisel F, Kulkarni S, Kerns RT, Hassan A, Deshmukh H, Nagarajan R, Frater JL and Cashen A: High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy. Cancer Genet. 204:129–137. 2011. View Article : Google Scholar : PubMed/NCBI
66	Collier MEW, Li C and Ettelaie C: The Influence of Tissue factor on the methylation of oestrogen receptor alpha gene during breast cancer. Thrombosis Res. 120:PO–77. 2007. View Article : Google Scholar
67	Zhang Y, Hyle J, Wright S, Shao Y, Zhao X, Zhang H and Li C: A cis-element within the ARF locus mediates repression of p16INK4A expression via long-range chromatin interactions. Proc Natl Acad Sci USA. 116:26644–22652. 2019. View Article : Google Scholar : PubMed/NCBI
68	Kobayashi T, Wang J, Al-Ahmadie H and Abate-Shen C: ARF regulates the stability of p16 protein via REGγ-dependent proteasome degradation. Mol Cancer Res. 11:828–833. 2013. View Article : Google Scholar : PubMed/NCBI